Scholarlink

Introduction <p>Brain metastases following esophagectomy for cancer are rare but can greatly affect quality of life. To date, risk factors for, time to development of, and treatment strategies for brain metastasis are not well defined.</p> Methods <p>Consecutive patients treated with esophagectomy for clinical stage I–IVA esophageal cancer from 2010 to 2021 across five centers were included. Logistic regression analyses were performed to identify risk factors for development of solitary brain metastases. Overall survival was assessed using Kaplan–Meier analysis.</p> Results <p>Of 3191 included patients, 91 (2.9%) developed solitary brain metastasis. Multivariable analysis identified increasing clinical nodal stage, adenocarcinoma (adjusted odds ratio [aOR] 4.00; 95% confidence interval [CI] 1.91–10), neoadjuvant chemoradiotherapy (aOR 2.18; 95% CI 1.19–4.28), and adjuvant therapy (OR 2.48; 95% CI 1.10–5.18) as risk factors for developing solitary brain metastases. Complete pathological responders were more likely to develop brain metastases than distant metastases (aOR 2.43; 95% CI 1.23–4.55). Patients with early solitary brain metastasis had the worst median overall survival (4.4 months, 95% CI 2.2–17) compared with classic (11 months, 95% CI 8.3–18) or late (7.4 months, 95% CI 2.1–not reached) (<i>p</i> = 0.20). Treatment involving surgery combined with radiation (adjusted hazard ratio [aHR] 0.10; 95% CI 0.05–0.20) resulted in better median overall survival (18 months, 95% CI 13–26) than did radiation (aHR 0.20; 95% CI 0.11–0.36) (10 months, 95% CI 6.1–14) or best supportive care (1.3 months, 95% CI 0.39–2.8) (<i>p</i> &lt; 0.001).</p> Conclusion <p>After esophagectomy for cancer, nodal involvement, adenocarcinoma, neoadjuvant and adjuvant therapy, and complete pathologic response appear to be risk factors for developing solitary brain metastases. Survival of selected patients with solitary brain metastasis is possible, especially if they are able to undergo surgery combined with radiation therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating Organotrophic Risk Factors, Time to Development, and Outcomes of Solitary Brain Metastasis After Esophagectomy: A Multicenter Cohort Study

  • 期刊论文

  • 发表日期：

    2025年11月1日

查看全文
  • Stijn Vanstraelen,
  • Johnny Moons,
  • Xing Gao,
  • Suzanne Gisbertz,
  • Julie Van Den Bosch,
  • Biying Huang,
  • Magnus Nilsson,
  • Meindert Sosef,
  • Mark I. van Berge Henegouwen,
  • Bas Wijnhoven,
  • Hans Van Veer,
  • Toni Lerut,
  • Philippe Nafteux,
  • Lieven Depypere

摘要

Introduction

Brain metastases following esophagectomy for cancer are rare but can greatly affect quality of life. To date, risk factors for, time to development of, and treatment strategies for brain metastasis are not well defined.

Methods

Consecutive patients treated with esophagectomy for clinical stage I–IVA esophageal cancer from 2010 to 2021 across five centers were included. Logistic regression analyses were performed to identify risk factors for development of solitary brain metastases. Overall survival was assessed using Kaplan–Meier analysis.

Results

Of 3191 included patients, 91 (2.9%) developed solitary brain metastasis. Multivariable analysis identified increasing clinical nodal stage, adenocarcinoma (adjusted odds ratio [aOR] 4.00; 95% confidence interval [CI] 1.91–10), neoadjuvant chemoradiotherapy (aOR 2.18; 95% CI 1.19–4.28), and adjuvant therapy (OR 2.48; 95% CI 1.10–5.18) as risk factors for developing solitary brain metastases. Complete pathological responders were more likely to develop brain metastases than distant metastases (aOR 2.43; 95% CI 1.23–4.55). Patients with early solitary brain metastasis had the worst median overall survival (4.4 months, 95% CI 2.2–17) compared with classic (11 months, 95% CI 8.3–18) or late (7.4 months, 95% CI 2.1–not reached) (p = 0.20). Treatment involving surgery combined with radiation (adjusted hazard ratio [aHR] 0.10; 95% CI 0.05–0.20) resulted in better median overall survival (18 months, 95% CI 13–26) than did radiation (aHR 0.20; 95% CI 0.11–0.36) (10 months, 95% CI 6.1–14) or best supportive care (1.3 months, 95% CI 0.39–2.8) (p < 0.001).

Conclusion

After esophagectomy for cancer, nodal involvement, adenocarcinoma, neoadjuvant and adjuvant therapy, and complete pathologic response appear to be risk factors for developing solitary brain metastases. Survival of selected patients with solitary brain metastasis is possible, especially if they are able to undergo surgery combined with radiation therapy.